We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




First-of-Its-Kind Blood Test Detects Over 50 Cancer Types

By LabMedica International staff writers
Posted on 15 Sep 2025

Many cancers lack routine screening, so patients are often diagnosed only after tumors grow and spread, when options are limited. More...

A faster, less invasive approach that broadens early detection could shift outcomes by finding the disease earlier. Now, a new blood-based multi-cancer test that analyzes multiple biomarker classes can enhance early cancer detection.

Exact Sciences (Madison, WI; USA) has launched Cancerguard, the first on-market multi-cancer early detection (MCED) test to assess multiple biomarker classes from a simple blood draw. The test can detect signals from cancers responsible for over 80% of U.S. diagnoses and covers 50+ cancer types and subtypes, including high-mortality diseases such as pancreatic and ovarian.

Normal cells regularly release a small amount of healthy DNA and protein into the bloodstream. If cancer is present in the body, the cancer also releases unhealthy DNA or other markers into the bloodstream. Cancerguard identifies these DNA and protein markers in the blood, thus helping find cancer earlier when it is more treatable. The Cancerguard test is intended for people aged 50-84 with no cancer diagnosis in the last 3 years.

In test-development studies, Cancerguard achieved 68% sensitivity across six of the deadliest cancers and 64% overall sensitivity (excluding breast and prostate), finding over one-third of stage I–II cases, with 97.4% specificity. Modeling suggests pairing Exact Sciences’ MCED technology with standard screening could cut stage IV diagnoses by 42% and reduce overall cancer mortality by 18% over 10 years.

“The Cancerguard test offers a critical early warning that cancer may be present and helps inform an imaging-guided pathway to diagnosis, giving people the chance to act when it matters most,” said Dr. Tom Beer, chief medical officer for multi-cancer early detection at Exact Sciences. “As adoption grows, we’ll look back and ask how we ever settled for screening for only a few cancers while letting the majority go undetected. Like the smartphone redefined communication, Cancerguard has the power to redefine cancer detection and the future of early intervention.”

Related Links:
Exact Sciences


Gold Member
Blood Gas Analyzer
Stat Profile pHOx
Collection and Transport System
PurSafe Plus®
Automated Chemiluminescence Immunoassay Analyzer
MS-i3080
Clinical Chemistry System
P780
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Hematology

view channel
Image: New evidence shows viscoelastic testing can improve assessment of blood clotting during postpartum hemorrhage (Photo courtesy of 123RF)

Viscoelastic Testing Could Improve Treatment of Maternal Hemorrhage

Postpartum hemorrhage, severe bleeding after childbirth, remains one of the leading causes of maternal mortality worldwide, yet many of these deaths are preventable. Standard care can be hindered by delays... Read more

Immunology

view channel
Image: Automated cell imaging discriminates CD8+ T cells according to natalizumab treatment outcome in MS patients (B Chaves et al., Nat Commun 16, 5533 (2025). DOI: 10.1038/s41467-025-60224-3)

Novel Tool Predicts Most Effective Multiple Sclerosis Medication for Patients

Multiple sclerosis (MS) is a chronic autoimmune and degenerative neurological disease that affects the central nervous system, leading to motor, cognitive, and mental impairments. Symptoms can include... Read more

Technology

view channel
Image: The SWITCH hybrid pipette is designed to simplify and accelerate pipetting tasks (Photo courtesy of INTEGRA)

Hybrid Pipette Combines Manual Control with Fast Electronic Aliquoting

Manual pipettes offer the control needed for delicate tasks such as mixing or supernatant removal, but typically fall short in repetitive workflows like aliquoting. Electronic pipettes solve this problem... Read more

Industry

view channel
Image: ELITechGroup’s unique Real-Time PCR technologies include the revolutionary Minor Groove Binder (Photo courtesy of ELITechGroup)

ELITech and Hitachi High-Tech to Develop Automated PCR Testing System for Infectious Diseases

Molecular testing has become central to diagnosing and monitoring infectious diseases by analyzing genetic information. The use of PCR during the COVID-19 pandemic showed its value, but traditional systems... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.